Immunoprecise Antibodies Ltd (IPA)

Apr 11, 2025, 8:40 AM EDT - 12 days ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Mar 28, 2025, 12:59 PM EDT - 26 days ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 8:01 AM EDT - 26 days ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 13, 2025, 7:02 AM EDT - 5 weeks ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 11, 2025, 10:17 PM EDT - 6 weeks ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 5, 2025, 8:01 AM EST - 7 weeks ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Feb 26, 2025, 8:01 AM EST - 2 months ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 24, 2025, 8:01 AM EST - 2 months ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 20, 2025, 8:01 AM EST - 2 months ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Jan 27, 2025, 8:01 AM EST - 3 months ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 22, 2025, 7:02 AM EST - 3 months ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 17, 2025, 8:01 AM EST - 3 months ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Dec 31, 2024, 7:56 PM EST - 4 months ago

IPA Announces Resignation of Chief Financial Officer

Dec 30, 2024, 10:03 PM EST - 4 months ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

Dec 23, 2024, 8:30 AM EST - 4 months ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

Dec 19, 2024, 10:15 AM EST - 4 months ago

IPA to Present at The Microcap Conference 2025

Dec 10, 2024, 5:33 PM EST - 4 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

Dec 10, 2024, 8:30 AM EST - 4 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dec 4, 2024, 8:00 AM EST - 5 months ago

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 3, 2024, 8:30 AM EST - 5 months ago

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

Nov 13, 2024, 9:00 AM EST - 5 months ago

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

Nov 4, 2024, 8:01 AM EST - 6 months ago

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

Oct 28, 2024, 7:30 AM EDT - 6 months ago

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

Oct 21, 2024, 9:00 AM EDT - 6 months ago

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

Oct 16, 2024, 2:54 PM EDT - 6 months ago

Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District

MMI

Oct 10, 2024, 8:10 AM EDT - 6 months ago

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

Oct 2, 2024, 8:00 AM EDT - 7 months ago

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

Sep 26, 2024, 9:00 AM EDT - 7 months ago

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

Sep 16, 2024, 1:46 PM EDT - 7 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript

Sep 16, 2024, 9:00 AM EDT - 7 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

Sep 9, 2024, 9:11 AM EDT - 8 months ago

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

Aug 26, 2024, 9:00 AM EDT - 8 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Aug 23, 2024, 8:00 PM EDT - 8 months ago

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

Aug 19, 2024, 9:00 AM EDT - 8 months ago

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

Jul 29, 2024, 8:36 PM EDT - 9 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript

Jul 29, 2024, 8:30 AM EDT - 9 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024

Jul 23, 2024, 7:30 PM EDT - 9 months ago

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024

Jul 16, 2024, 8:01 PM EDT - 10 months ago

ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures

Jul 15, 2024, 8:31 AM EDT - 10 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024

Jun 27, 2024, 8:01 AM EDT - 10 months ago

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

Jun 25, 2024, 7:02 AM EDT - 10 months ago

IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

Jun 12, 2024, 7:00 AM EDT - 11 months ago

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

Jun 10, 2024, 7:15 AM EDT - 11 months ago

BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

Jun 4, 2024, 7:00 AM EDT - 11 months ago

IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)

Apr 22, 2024, 9:00 AM EDT - 1 year ago

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results

Apr 12, 2024, 9:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

Mar 28, 2024, 7:02 AM EDT - 1 year ago

InterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

Mar 20, 2024, 7:02 AM EDT - 1 year ago

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Mar 14, 2024, 2:49 PM EDT - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript

Mar 14, 2024, 8:05 AM EDT - 1 year ago

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*